BioCentury
ARTICLE | Clinical News

Erytech sinks after Graspa miss in AML study

December 8, 2017 11:44 PM UTC

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) lost $8.80 (31%) to $19.20 on NASDAQ Friday after it said Graspa eryaspase missed the primary endpoint in a Phase IIb trial to treat newly diagnosed acute myelogenous leukemia in patients ineligible for intensive chemotherapy. The company fell €7.21 (31%) to €16.34 on Euronext.

On the 123-patient trial's primary endpoint, Graspa plus low-dose cytarabine failed to improve overall survival (OS) vs. cytarabine alone (HR=1.06, 95% CI: 0.7, 1.61). Erytech said the median duration of treatment was less than two months for both arms...